Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cisplatin + KPT-185|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 6||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|KPT-185||KPT185||KPT-185 is a small molecule inhibitor of the nuclear export, XPO1 (CRM1), preventing export of tumor suppressor proteins thereby possibly restoring tumor suppressor function in the cell and thus, leading to apoptotic activity (PMID: 25579209). KPT-185 has been demonstrated to be unsuitable for in vivo studies due to weak pharmacokinetic properties (PMID: 23373539).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||Cisplatin + KPT-185||Preclinical - Patient cell culture||Actionable||In a preclinical study, the combination of KPT-185 and Platinol (cisplatin) worked synergistically to decrease viability of platinum-resistant and platinum-sensitive immortalized and patient-derived human ovarian cancer cell lines in culture (PMID: 27649553).||27649553|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|